Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) Income towards Parent Company (2016 - 2026)

Nutex Health (NUTX) has disclosed Income towards Parent Company for 14 consecutive years, with $62.8 million as the latest value for Q1 2026.

  • For Q1 2026, Income towards Parent Company rose 23.53% year-over-year to $62.8 million; the TTM value through Mar 2026 reached $192.3 million, up 31.09%, while the annual FY2025 figure was $180.4 million, 90.24% up from the prior year.
  • Income towards Parent Company hit $62.8 million in Q1 2026 for Nutex Health, up from $16.6 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $100.0 million in Q4 2024 and bottomed at -$422.9 million in Q3 2022.
  • Average Income towards Parent Company over 5 years is -$8.1 million, with a median of -$542000.0 recorded in 2024.
  • Year-over-year, Income towards Parent Company tumbled 159.99% in 2023 and then surged 9473.8% in 2025.
  • Nutex Health's Income towards Parent Company stood at -$10.7 million in 2022, then crashed by 159.99% to -$27.7 million in 2023, then skyrocketed by 461.03% to $100.0 million in 2024, then plummeted by 83.4% to $16.6 million in 2025, then soared by 277.91% to $62.8 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at $62.8 million, $16.6 million, and $96.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.